Penetration into tear fluid and clinical evaluation of fluoroquinolone pazufloxacin for external infectious eye diseases

• Published in: Japanese Journal of Chemotherapy Vol. 43; no. Supplement2; pp. 512 - 514
• Main Authors: Shu, Seisei, Fukuda, Masamichi, Karino, Kousei, Sasaki, Kazuyuki
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1995; 公益社団法人 日本化学療法学会
• Subjects: PZFX; フルオロキノロン系抗菌薬; 外眼部感染症; 涙液中薬剤濃度
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.43.Supplement2_512

The penetration of a newly developed fluoroquinolone, pazufloxacin, into the tear fluid in the healthy human adult cul-de-sac and into serum were examined. The highest drug concentrations after 200 mg of orally administration in tear fluid and serum from 30 minutes to 24 hours were 0.45±0.33μg/ml and 2.07μg/ml, respectively. A drug concentraion in tear fluid of 0.11±0.07μg/ml was noticed even 6 hours after the administraion. In 8 clinical cases with external inflammatory ocular diseases, 100 mg or 200 mg of the drug was administered daily three times for 4 to 7 days. Marked effectiveness and of effectiveness were seen 3 and 4 cases, respectively, and no change was seen in one case.